NCT02982005

A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of KHK4827 in Subjects With Moderate to Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: Kyowa Kirin Korea Co., Ltd. · Industry
• Sex: All
• Age: 20 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis randomized in a double-blind manner to receive KHK4827 or placebo for 12 weeks

Conditions

• Moderate to Severe Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	KHK4827	Administered KHK4827 by subcutaneous (SC) injection until week 62.
DRUG	Placebo	Administered placebo by subcutaneous (SC) injection until week 12. Administered KHK4827 by SC injection from week 13 until week 62.

Timeline

• Start date: 2017-01-01
• Primary completion: 2018-08-14
• Completion: 2018-08-14
• First posted: 2016-12-05
• Last updated: 2024-04-29

Locations

1 site across 1 country: South Korea